Phosphodiesterase 4 (PDE4) is an enzyme known to play a role in inflammatory responses, and it has been pinpointed as an interesting therapeutic target for diseases like atopic dermatitis (AD), but limited efficacy and side effects have prevented the approval of oral formulations.
Darier disease (DD) is a rare cutaneous disease caused by heterozygous mutations in the ATP2A2 gene, which encodes sarco/endoplasmic reticulum calcium ATPase isoform 2 (SERCA2).
Artelo Biosciences Inc. has presented data on its fatty acid-binding protein 5 (FABP5) inhibitor ART-26.12 from testing of its efficacy in preclinical models of psoriasis.
Researchers from Teva Pharmaceutical Industries Ltd. have presented data from preclinical studies evaluating the novel humanized human-proteinase‑activated receptor 2 (PAR2)-specific monoclonal antibody, TEV-56192, as potential treatment of skin inflammatory conditions.
Haihe Biopharma Co. Ltd. has described androgen receptor antagonists reported to be useful for the treatment of acne, androgenic alopecia, breast and prostate cancer, benign prostatic hyperplasia, hidradenitis suppurativa, hirsutism and prostatitis.
Atopic dermatitis is a systemic inflammatory disorder where both innate immune cells such as dendritic cells (DCs) and adaptive immune cells, such as B and T cells, contribute to cutaneous inflammation. B and T lymphocyte attenuator (BTLA), highly expressed in mature DCs, is crucial to modulate the activity of all immune cells and acts as a co-inhibitory checkpoint receptor.
Researchers from Paragon Therapeutics Inc. presented the preclinical characterization of ORKA-001 (PR-035), a novel half-life extended monoclonal antibody targeting the p19 subunit of IL-23, designed to treat chronic skin disorders such as plaque psoriasis.
RSS
